Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) were down 1.7% during trading on Friday . The company traded as low as $9.76 and last traded at $9.80, with a volume of 628,839 shares traded. The stock had previously closed at $9.97.

A number of analysts have recently commented on HALO shares. Jefferies Group reissued a “sell” rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Canaccord Genuity reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Wells Fargo & Co. reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $15.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Buy” and an average price target of $15.68.

The stock’s market capitalization is $1.26 billion. The firm’s 50 day moving average is $9.83 and its 200-day moving average is $9.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. During the same period in the previous year, the firm earned $0.02 EPS. The firm earned $33.30 million during the quarter, compared to analysts’ expectations of $29.94 million. The firm’s revenue was down 23.3% on a year-over-year basis. Equities analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.